{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T02:59:20Z","timestamp":1791082760095,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2018,4,27]],"date-time":"2018-04-27T00:00:00Z","timestamp":1524787200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Hepatology"],"published-print":{"date-parts":[[2018,9]]},"abstract":"\n Hepatitis B virus (HBV) RNA in serum is a novel biomarker for intrahepatic HBV replication and treatment response. For its proper use, it is essential to identify factors influencing serum HBV RNA level. Using a rapid amplification of complimentary DNA (cDNA) ends (RACE) PCR technique (lower limit of detection [LLD], 800 copies\/mL [c\/mL]), serum HBV RNA levels were measured in samples of 488 untreated individuals with chronic HBV infection who were eligible to treatment according to currently used recommendations. We explored the association of serum levels of HBV RNA with patient\u2010 and virus\u2010associated factors. HBV genotype distribution was 21\/10\/20\/46\/3% for A\/B\/C\/D\/other. Mean HBV RNA serum level was 5.9 (1.6) log\n 10<\/jats:sub>\n c\/mL (hepatitis B e antigen [HBeAg]\u2010positive chronic hepatitis B [CHB], 6.5 [1.2] log c\/mL; HBeAg\u2010negative CHB, 4.1 [1.2] log c\/mL;\n P <<\/jats:italic>\n 0.001). By multivariable linear regression, factors associated with lower HBV RNA level were HBeAg negativity (\u03b2 = \u20130.69;\n P<\/jats:italic>\n < 0.001), HBV genotypes A (\u03b2 = \u20130.13;\n P =<\/jats:italic>\n 0.002), B (\u03b2 = \u20130.07;\n P<\/jats:italic>\n = 0.049), and C (\u03b2 = \u20130.61;\n P<\/jats:italic>\n < 0.001) in comparison to D, and presence of HBV basal core promoter mutation either alone (\u03b2 = \u20130.14;\n P<\/jats:italic>\n = 0.001) or in combination with precore mutation (\u03b2 = \u20130.22;\n P<\/jats:italic>\n < 0.001). Higher serum alanine aminotransferase (ALT) was associated with higher HBV RNA (\u03b2 = 0.23;\n P<\/jats:italic>\n < 0.001). HBV RNA correlated strongly with HBV DNA (HBeAg\u2010pos, r = 0.72;\n P<\/jats:italic>\n < 0.001; HBeAg\u2010neg, r = 0.78;\n P<\/jats:italic>\n < 0.001) and moderately with quantitative hepatitis B surface antigen (qHBsAg; HBeAg\u2010pos, r = 0.54;\n P<\/jats:italic>\n < 0.001; HBeAg\u2010neg, r = 0.19;\n P<\/jats:italic>\n = 0.04) and quantitative hepatitis B surface antigen (qHBeAg; r = 0.41;\n P<\/jats:italic>\n < 0.001).\n Conclusion:<\/jats:italic>\n In this multiethnic cohort of 488 untreated individuals with CHB, factors associated with serum HBV RNA level were HBeAg status, serum ALT, HBV genotype, and presence of basal core promotor mutations. For the future use of serum HBV RNA as a clinical marker, it seems mandatory to take these factors into consideration. (H\n epatology<\/jats:sc>\n 2018).\n <\/jats:p>","DOI":"10.1002\/hep.29872","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T18:32:35Z","timestamp":1520447555000},"page":"839-847","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":83,"title":["Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment"],"prefix":"10.1097","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0460-4920","authenticated-orcid":false,"given":"Margo J.H.","family":"van Campenhout","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Erasmus MC University Medical Center,Rotterdam,The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"van B\u00f6mmel","sequence":"additional","affiliation":[{"name":"University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology,Leipzig,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Pfefferkorn","sequence":"additional","affiliation":[{"name":"University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology,Leipzig,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janett","family":"Fischer","sequence":"additional","affiliation":[{"name":"University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology,Leipzig,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Deichsel","sequence":"additional","affiliation":[{"name":"University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology,Leipzig,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Boonstra","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Erasmus MC University Medical Center,Rotterdam,The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke J.","family":"van Vuuren","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Erasmus MC University Medical Center,Rotterdam,The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Berg","sequence":"additional","affiliation":[{"name":"University Hospital Leipzig, Department of Gastroenterology and Rheumatology, Section of Hepatology,Leipzig,Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Erasmus MC University Medical Center,Rotterdam,The Netherlands"},{"name":"Institute of Health Policy, Management and Evaluation,University of Toronto"},{"name":"Toronto Center for Liver Disease, Toronto Western and General Hospital,University Health Network,Toronto,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology,Erasmus MC University Medical Center,Rotterdam,The Netherlands"},{"name":"Toronto Center for Liver Disease, Toronto Western and General Hospital,University Health Network,Toronto,Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2018,4,27]]},"reference":[{"key":"hep29872-bib-0001-20251105","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","year":"2015","journal-title":"Gut"},{"key":"hep29872-bib-0002-20251105","first-page":"336A","article-title":"Serum HBV RNA is an early predictor of HBeAg seroconversion in patients with chronic Hepatitis B (CHB) treated with pegylated interferon alfa\u20102a (40KD)","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep29872-bib-0003-20251105","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","year":"2016","journal-title":"J Hepatol"},{"key":"hep29872-bib-0004-20251105","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1093\/infdis\/jiv397","article-title":"Hepatitis B virus pregenomic RNA is present in virions in plasma and is associated with a response to pegylated interferon alfa\u20102a and nucleos(t)ide analogues","volume":"213","year":"2016","journal-title":"J Infect Dis"},{"key":"hep29872-bib-0005-20251105","doi-asserted-by":"crossref","first-page":"eaan0241","DOI":"10.1126\/scitranslmed.aan0241","article-title":"RNAi\u2010based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg","volume":"9","year":"2017","journal-title":"Sci Transl Med"},{"key":"hep29872-bib-0006-20251105","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jhep.2016.10.034","article-title":"Reply to: \u201cSerum HBV pgRNA as a clinical marker for cccDNA activity\u201d: consistent loss of serum HBV RNA might predict the \u201cpara\u2010functional cure\u201d of chronic hepatitis B","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep29872-bib-0007-20251105","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep29872-bib-0008-20251105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3851\/IMP2777","article-title":"On\u2010treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy","volume":"20","year":"2015","journal-title":"Antivir Ther"},{"key":"hep29872-bib-0009-20251105","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00535-012-0737-2","article-title":"Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients","volume":"48","year":"2013","journal-title":"J Gastroenterol"},{"key":"hep29872-bib-0010-20251105","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"hep29872-bib-0011-20251105","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1002\/hep.27586","article-title":"Adding pegylated interferon to entecavir for hepatitis B e antigen\u2010positive chronic hepatitis B: a multicenter randomized trial (ARES study)","volume":"61","year":"2015","journal-title":"Hepatology"},{"key":"hep29872-bib-0012-20251105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa\u20102b alone or in combination with lamivudine for HBeAg\u2010positive chronic hepatitis B: a randomised trial","volume":"365","year":"2005","journal-title":"Lancet"},{"key":"hep29872-bib-0013-20251105","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1038\/ajg.2010.186","article-title":"A randomized trial of peginterferon alpha\u20102a with or without ribavirin for HBeAg\u2010negative chronic hepatitis B","volume":"105","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"hep29872-bib-0014-20251105","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1053\/j.gastro.2008.05.031","article-title":"Sustained HBeAg and HBsAg loss after long\u2010term follow\u2010up of HBeAg\u2010positive patients treated with peginterferon alpha\u20102b","volume":"135","year":"2008","journal-title":"Gastroenterology"},{"key":"hep29872-bib-0015-20251105","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","year":"2017","journal-title":"J Hepatol"},{"key":"hep29872-bib-0016-20251105","first-page":"895A","article-title":"The level of HBV RNA in serum as a novel marker for the phase of chronic hepatitis B virus (HBV) infections","volume":"63","year":"2016","journal-title":"Hepatology"},{"key":"hep29872-bib-0017-20251105","first-page":"222A","article-title":"Reductions in cccDNA under NUC and ARC\u2010520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBSAG","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"hep29872-bib-0018-20251105","doi-asserted-by":"crossref","first-page":"e112306","DOI":"10.1371\/journal.pone.0112306","article-title":"Clinical application of estimating hepatitis B virus quasispecies complexity by massive sequencing: correlation between natural evolution and on\u2010treatment evolution","volume":"9","year":"2014","journal-title":"PLoS One"},{"key":"hep29872-bib-0019-20251105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0168-8278(02)00349-5","article-title":"Precore and core promoter mutations of hepatitis B virus and hepatitis B e antigen\u2010negative chronic hepatitis B in Korea","volume":"38","year":"2003","journal-title":"J Hepatol"},{"key":"hep29872-bib-0020-20251105","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1006\/viro.2001.1352","article-title":"In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter","volume":"295","year":"2002","journal-title":"Virology"},{"key":"hep29872-bib-0021-20251105","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1128\/JVI.73.2.1239-1244.1999","article-title":"Mechanism of suppression of hepatitis B virus precore RNA transcription by a frequent double mutation","volume":"73","year":"1999","journal-title":"J Virol"},{"key":"hep29872-bib-0022-20251105","doi-asserted-by":"crossref","first-page":"17950","DOI":"10.1038\/srep17950","article-title":"Deep sequencing of hepatitis B virus basal core promoter and precore mutants in HBeAg\u2010positive chronic hepatitis B patients","volume":"5","year":"2015","journal-title":"Sci Rep"},{"key":"hep29872-bib-0023-20251105","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1172\/JCI86650","article-title":"New perspectives on the hepatitis B virus life cycle in the human liver","volume":"126","year":"2016","journal-title":"J Clin Invest"},{"key":"hep29872-bib-0024-20251105","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1053\/jhep.2000.19623","article-title":"No significant correlation exists between core promoter mutations, viral replication, and liver damage in chronic hepatitis B infection","volume":"32","year":"2000","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.29872","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201809000-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:01:12Z","timestamp":1762376472000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201809000-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,27]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.29872","relation":{},"ISSN":["0270-9139","1527-3350"],"issn-type":[{"value":"0270-9139","type":"print"},{"value":"1527-3350","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,27]]},"assertion":[{"value":"2017-11-05","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}